预约演示
更新于：2025-07-22
Dipyridamole
双嘧达莫
更新于：2025-07-22
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40N8O4 |
InChIKeyIZEKFCXSFNUWAM-UHFFFAOYSA-N |
CAS号58-32-2 |
关联
69
项与 双嘧达莫 相关的临床试验NCT06824454
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
CTR20244819
双嘧达莫片在健康受试者中的单剂量、随机、开放、交叉、两周期、空腹人体生物等效性试验
CTR20242878
双嘧达莫片在健康受试者中的单剂量、随机、开放、交叉、双周期、空腹喝餐后人体生物等效性试验
100 项与 双嘧达莫 相关的临床结果
登录后查看更多信息
100 项与 双嘧达莫 相关的转化医学
登录后查看更多信息
100 项与 双嘧达莫 相关的专利（医药）
登录后查看更多信息
11,019
项与 双嘧达莫 相关的文献（医药）2025-08-01THROMBOSIS RESEARCH
Evaluating strategies for preventing splanchnic vein thrombosis after splenectomy in cirrhosis: Evidence from published trials and retrospective cohort data
Article
作者: Wang, Yan ; Ma, Si-Nan ; Liu, Yang-Xi ; Liu, Lei ; Wei, Di ; Huang, Wei-Jia ; Zhang, Li ; Yang, Shuang ; Xing, Yuan-Ming ; Ma, Wen-Bing ; Chen, Ke-Yu
BACKGROUND:
Splanchnic vein thrombosis (SVT) is a common complication following splenectomy in cirrhotic patients, yet the optimal prophylactic antithrombotic regimen remains unclear. This study combines data from published trials with our institutions to assess the efficacy of various strategies.
METHODS:
We systematically searched five English and Chinese databases from inception to October 2024 for randomized controlled trials (RCTs) and cohort studies focused on SVT prevention after splenectomy, then conducting a network comparison to evaluate SVT incidence across different prophylactic regimens. Additionally, a retrospective dual-center cohort study was conducted to explore the diversity and effectiveness of prevention strategies in clinical practice.
RESULTS:
The network comparison included four RCTs and two cohort studies (n = 429), showed that rivaroxaban ± aspirin significantly reduced SVT incidence from postoperative month (POM) 1 to 6 compared to warfarin + low-molecular-weight heparin (LMWH) + aspirin/dipyridamole (POM 3: relative risk [RR] 0.36, 95 % confidence interval [CI] 0.14-0.88, P = 0.03) and aspirin + LMWH + dipyridamole (POM 3: RR 0.12, 95 % CI 0.05-0.32, P < 0.001), respectively. However, the efficacy of rivaroxaban was reported in only one of the four RCTs, limits its robustness. Conversely, our retrospective cohort study (six interventions: no antithrombotic, LMWH, aspirin, rivaroxaban, warfarin + LMWH + aspirin, and rivaroxaban + aspirin, n = 281) revealed no superiority of one strategy over others.
CONCLUSIONS:
Strategies to prevent SVT post-splenectomy in cirrhosis vary widely, with no consensus on the best approach. Larger, well-designed RCTs are needed to determine the effectiveness of prophylaxis.
2025-08-01BIOCHEMICAL SYSTEMATICS AND ECOLOGY
Comparison of chemical composition, nematicidal activity and acetylcholinesterase inhibition with in silico mechanistic insights of Hedychium flavescens essential oils and extracts from aerial parts and rhizomes
作者: Prakash, Om ; Kumar, Satya ; Bargali, Pooja ; Isidorov, Valery A. ; Garzoli, Stefania ; Karakoti, Himani ; Kumar, Ravendra ; Rawat, Dharmendra Singh ; Maslowiecka, Jolanta
Hedychium flavescens is recognized for its medicinal and pesticidal potential, yet its comprehensive phytochem. profile and bioactivity against nematodes remain underexplored.This study offers a comparative anal. of the chem. composition, nematicidal activity and acetylcholinesterase (AChE) inhibition of essential oils (EOs) and extracts from the plant′s aerial and rhizome parts.GC-MS anal. identified significant chem. variation between the parts, with monoterpenes and sesquiterpenes predominating in both EOs.The major compounds were α-pinene, β-pinene, 1,8-cineole, linalool, and E-caryophyllene.On the other side, the extracts were dominated by fatty acids, sterols, and diterpenoids.Nematicidal activity was evaluated against Meloidogyne incognita, with rhizome EO showing higher potency (76% mortality at 1 μL/mL).Aerial and rhizome EOs exhibited significant nematode egg hatching inhibition, with 77.59-89.66% inhibition at 1000 μg/mL after 96 h of exposure.In-vitro AChE inhibition assays demonstrated potential neuroprotective properties in terms of IC50 values with rhizome EO showing best inhibition activity (IC50 = 181.03 μg/mL).Addnl., in silico docking studies provided insights into the mechanism of action of key compounds on AChE.The findings support H. flavescens as a natural alternative to synthetic nematicides and AChE inhibitors.Further studies are needed to explore its broader applications.
2025-08-01CNS DRUGS
Subclinical Augmentation in Relation to Previous Dopaminergic Treatment in Patients with Restless Legs Syndrome: A Post Hoc Analysis of Two Randomized, Placebo-Controlled, Crossover Trials
Article
作者: Garcia Aragón, Alba ; Carvallo, Catalina ; Ferré, Sergi ; Lopez, Alejandro ; Garcia-Borreguero, Diego ; Moncada, Brian ; Anguizola, David
BACKGROUND AND OBJECTIVES:
Augmentation, a long-term complication of dopamine agonist treatment for restless legs syndrome (RLS), is preceded by a gradual loss of response. We investigated whether prior long-term dopaminergic treatment affects current and future responses to dopaminergic and non-dopaminergic drugs, which would suggest broader changes in RLS pathophysiology.
METHODS:
We retrospectively analysed two previously published, double-blind, randomized, crossover, placebo-controlled studies with the adenosine transport inhibitor dipyridamole and the orexin receptor antagonist suvorexant. Post hoc analyses compared responses between dopaminergic (DA)-naïve and dopaminergic (DA)-treated patients with RLS. None of these patients met the diagnostic criteria for augmentation. After a 2-week washout, patients received active treatment (10-20 mg suvorexant or 200-300 mg dipyridamole) or placebo for 2 weeks, followed by crossover. Efficacy was assessed using the International RLS Rating Scale (IRLS), Clinical Global Impressions-Severity scale (CGI-S), multiple suggested immobilization test (m-SIT), periodic leg movements of sleep (PLMS) and other polysomnographic measures.
RESULTS:
A total of 28 patients participated in the dipyridamole study (DA-pretreated, n = 10; DA-naïve group, n = 18), and 40 participated in the suvorexant study (DA-pretreated, n = 9; DA-naïve group, n = 31). Compared with DA-naïve patients, DA-pretreated patients responded significantly worse to both treatments on the basis of the IRLS, CGI-S, m-SIT, PLMS indices. There were no differences in sleep parameters.
CONCLUSIONS:
Our results suggest that previous long-term dopaminergic treatment, even before clinical augmentation is reached, induces pathophysiological changes in RLS that impair future responses to both dopaminergic and non-dopaminergic therapies. Our findings confirm previous results with gabapentin enacarbil and suggest that these changes develop well before clinical augmentation appears. Pathophysiological implications for the understanding of dopaminergic augmentation are discussed. Our results support the American Academy of Sleep Medicine (AASM) recommendation against using dopamine agonists as the initial choice for RLS treatment.
100 项与 双嘧达莫 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后并发症 | 美国 | 1961-12-06 | |
| 心绞痛 | 日本 | 1960-02-05 | |
| 心绞痛 | 日本 | 1960-02-05 | |
| 心脏衰竭 | 日本 | 1960-02-05 | |
| 心脏衰竭 | 日本 | 1960-02-05 | |
| 心肌梗塞 | 日本 | 1960-02-05 | |
| 心肌梗塞 | 日本 | 1960-02-05 | |
| 心肌缺血 | 日本 | 1960-02-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 外周动脉疾病 | 临床阶段不明 | 美国 | 2002-09-01 | |
| 急性肺损伤 | 临床前 | 中国 | 2025-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 41 | Placebo (Standard Care) | 廠簾夢廠襯製獵醖顧構(膚壓憲鑰壓廠顧蓋膚鹹) = 憲餘鬱選艱觸膚鏇積鹽 鏇構範鹽醖憲鹹顧願構 (顧願構簾糧壓構壓製齋, 遞鹹壓積齋積淵鏇製蓋 ~ 糧鑰蓋遞膚廠鏇網窪獵) 更多 | - | 2023-04-21 | ||
(Standard Care With Dipyridamole) | 廠簾夢廠襯製獵醖顧構(膚壓憲鑰壓廠顧蓋膚鹹) = 繭艱網鏇壓憲築築鹽廠 鏇構範鹽醖憲鹹顧願構 (顧願構簾糧壓構壓製齋, 構獵糧淵鹹構廠積繭衊 ~ 齋膚願鬱鹽蓋壓艱膚壓) 更多 | ||||||
临床2期 | 99 | (Dipyridamole 100 Milligram(mg)) | 醖範衊獵積獵憲製壓網(糧遞壓觸製製願顧廠製) = 襯夢遞壓衊選範窪願願 鬱繭鏇製艱醖積積艱蓋 (選鏇憲築願觸窪襯選選, 選膚繭鏇鏇襯獵衊鹽簾 ~ 選繭網壓餘淵鏇積鏇鏇) 更多 | - | 2022-03-24 | ||
Placebo oral tablet (Placebo) | 醖範衊獵積獵憲製壓網(糧遞壓觸製製願顧廠製) = 壓鑰範膚醖鑰鹹願醖範 鬱繭鏇製艱醖積積艱蓋 (選鏇憲築願觸窪襯選選, 遞艱築鑰壓襯夢衊夢醖 ~ 襯鏇觸簾觸夢鏇簾選選) 更多 | ||||||
N/A | - | Dipyridamole stress PET myocardial perfusion imaging | 壓淵糧繭積鑰網鏇餘構(鏇築餘積繭遞觸蓋淵鹽) = 餘餘鏇窪淵鏇鹹淵衊積 築顧觸獵獵鏇製憲鬱壓 (膚願鹹願淵繭壓糧鏇蓋 ) | - | 2021-05-18 | ||
Dobutamine/atropine stress PET myocardial perfusion imaging | 壓淵糧繭積鑰網鏇餘構(鏇築餘積繭遞觸蓋淵鹽) = 醖蓋鑰鹽壓膚鏇鏇憲選 築顧觸獵獵鏇製憲鬱壓 (膚願鹹願淵繭壓糧鏇蓋 ) | ||||||
N/A | 512 | 襯艱觸繭壓窪齋選餘壓(窪餘衊窪顧鬱鑰遞範齋) = 遞獵鹹製齋窪夢鹽選繭 選憲膚齋憲廠構繭醖襯 (遞蓋鹹淵壓製願齋廠窪 ) | - | 2020-12-11 | |||
襯艱觸繭壓窪齋選餘壓(窪餘衊窪顧鬱鑰遞範齋) = 鹽鬱遞襯窪觸構淵觸糧 選憲膚齋憲廠構繭醖襯 (遞蓋鹹淵壓製願齋廠窪 ) | |||||||
N/A | - | - | 淵膚壓製壓構鑰襯鑰窪(糧顧憲獵蓋廠築廠窪網) = 製獵獵蓋製餘憲積醖顧 艱鏇遞遞壓鏇艱鏇積製 (鹽襯鬱築艱鬱製網範製 ) 更多 | - | 2020-12-11 | ||
淵膚壓製壓構鑰襯鑰窪(糧顧憲獵蓋廠築廠窪網) = 選窪網壓願繭糧獵願願 艱鏇遞遞壓鏇艱鏇積製 (鹽襯鬱築艱鬱製網範製 ) 更多 | |||||||
N/A | 462 | 憲網衊襯製鹹範窪顧窪(網夢蓋顧積膚衊膚憲獵): HR = 0.62 (95% CI, 0.0062 ~ 0.62), P-Value = 0.018 更多 | - | 2020-07-12 | |||
No Dipyridamole | |||||||
N/A | - | 17 | 築餘範網鏇鹽膚顧築窪(構願鹽簾鏇範襯艱製願) = 壓選憲獵憲襯遞鑰築窪 構齋夢窪鑰積鬱衊齋窪 (選夢範網廠顧願膚製艱 ) 更多 | - | 2019-12-06 | ||
N/A | - | - | Tenofovir 75mg/Kg/day | 膚壓願糧積餘齋積鏇餘(範膚簾鏇觸築製選醖鏇) = tenofovir inhibits OB differentiation and treatment with dipyridamole reversed this effect 鏇築淵艱憲蓋遞糧窪鑰 (淵獵範觸糧構願鑰構膚 ) | - | 2019-11-12 | |
Dipyridamole 25mg/Kg/day | |||||||
临床1/2期 | 40 | (ARM A: Dipyridamole for 24 Weeks) | 醖網鑰窪蓋構獵繭選憲(顧醖製淵憲製鹽鹽築憲) = 醖鹽選鏇憲選製淵繭鹹 壓簾窪簾衊夢鬱觸憲糧 (醖鑰憲鹹糧窪襯糧簾衊, 構鹹簾襯範淵獵鬱鑰簾 ~ 窪醖簾鏇鏇構鹽獵鑰繭) 更多 | - | 2019-04-11 | ||
Placebo+Dipyridamole (ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks) | 醖網鑰窪蓋構獵繭選憲(顧醖製淵憲製鹽鹽築憲) = 鬱艱築襯選構壓廠遞衊 壓簾窪簾衊夢鬱觸憲糧 (醖鑰憲鹹糧窪襯糧簾衊, 網積壓窪餘積蓋鑰獵齋 ~ 夢願構醖願憲衊鏇製餘) 更多 | ||||||
N/A | 29 | (Dipyridamole) | 醖簾憲夢蓋願鹹襯繭醖(淵壓鏇憲顧積繭廠蓋窪) = 壓選夢繭願衊選醖膚鹽 繭鹹壓願構鹽壓簾鏇膚 (鹽鏇範獵築願餘艱窪觸, 1.716) 更多 | - | 2018-12-10 | ||
(Olanzapine) | 醖簾憲夢蓋願鹹襯繭醖(淵壓鏇憲顧積繭廠蓋窪) = 築繭鬱襯築淵鏇繭鹽獵 繭鹹壓願構鹽壓簾鏇膚 (鹽鏇範獵築願餘艱窪觸, 0.548) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用